Early disease detection and treatment effectiveness for solid tumors often involves
highly invasive procedures for the patient. Liquid biopsies offer a minimally invasive,
high-throughput method to detect cancer earlier and monitor treatment effects without severe adverse effects on patients. Validating new liquid biopsy tests requires extensive, highly clinically annotated diseased and normal biospecimens.
